[go: up one dir, main page]

PE20151771A1 - Composiciones nutricionales que contienen un componente neurologico y los usos del mismo - Google Patents

Composiciones nutricionales que contienen un componente neurologico y los usos del mismo

Info

Publication number
PE20151771A1
PE20151771A1 PE2015001304A PE2015001304A PE20151771A1 PE 20151771 A1 PE20151771 A1 PE 20151771A1 PE 2015001304 A PE2015001304 A PE 2015001304A PE 2015001304 A PE2015001304 A PE 2015001304A PE 20151771 A1 PE20151771 A1 PE 20151771A1
Authority
PE
Peru
Prior art keywords
nutritional compositions
neurological component
neurological
same
compositions containing
Prior art date
Application number
PE2015001304A
Other languages
English (en)
Inventor
Chenzhong Kuang
Yan Xiao
Eduard K Poels
Zeina Jouni
Dirk Hondmann
Original Assignee
Mjn Us Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mjn Us Holdings Llc filed Critical Mjn Us Holdings Llc
Publication of PE20151771A1 publication Critical patent/PE20151771A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pediatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE REFIERE A COMPOSICIONES NUTRICIONALES QUE COMPRENDEN UN COMPONENTE NEUROLOGICO, EL CUAL PUEDE INCLUIR FOSFATIDILETANOLAMINA, ESFINGOMIELINA, CITIDINA-DIFOSFOCOLINA, CERAMIDA, URIDINA, AL MENOS UN GANGLIOSIDO, Y MEZCLAS DE LOS MISMOS. DICHO COMPONENTE NEUROLOGICO PROMUEVE EL DESARROLLO DEL CEREBRO Y EL SISTEMA NERVIOSO Y ADEMAS PROPORCIONA PROTECCION Y REPARACION NEUROLOGICA. TAMBIEN SE REFIERE A METODOS PARA PROMOVER LA SALUD DEL CEREBRO Y EL SISTEMA NERVIOSO, PROPORCIONANDO DICHAS COMPOSICIONES NUTRICIONALES A SUJETOS OBJETIVOS QUE INCLUYE A PACIENTES PEDIATRICOS
PE2015001304A 2013-01-11 2013-12-12 Composiciones nutricionales que contienen un componente neurologico y los usos del mismo PE20151771A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/739,787 US20140199265A1 (en) 2013-01-11 2013-01-11 Nutritional compositions containing a neurologic component and uses thereof

Publications (1)

Publication Number Publication Date
PE20151771A1 true PE20151771A1 (es) 2015-12-02

Family

ID=49887324

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001304A PE20151771A1 (es) 2013-01-11 2013-12-12 Composiciones nutricionales que contienen un componente neurologico y los usos del mismo

Country Status (16)

Country Link
US (1) US20140199265A1 (es)
EP (1) EP2943079A1 (es)
CN (1) CN104883909A (es)
AR (1) AR094413A1 (es)
AU (1) AU2013372898B2 (es)
BR (1) BR112015016358A2 (es)
CA (1) CA2912246A1 (es)
HK (1) HK1214090A1 (es)
IN (1) IN2015DN04207A (es)
MX (1) MX2015008585A (es)
PE (1) PE20151771A1 (es)
PH (1) PH12015501504A1 (es)
RU (1) RU2015120263A (es)
SG (1) SG11201503682VA (es)
TW (1) TW201440669A (es)
WO (1) WO2014109862A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9661874B2 (en) 2013-03-11 2017-05-30 Mead Johnson Nutrition Company Nutritional compositions containing structured fat globules and uses thereof
US10455854B2 (en) 2013-03-11 2019-10-29 Mead Johnson Nutrition Company Nutritional compositions containing structured fat globules and uses thereof
US9980506B2 (en) 2013-03-11 2018-05-29 Mead Johnson Nutrition Co. Nutritional compositions containing structured fat globules and uses thereof
US9226914B2 (en) 2013-07-16 2016-01-05 Mead Johnson Nutrition Company Methods for promoting neuronal development and/or health
US9241923B2 (en) 2013-07-16 2016-01-26 Mead Johnson Nutrition Company Methods for promoting neuronal development and/or health
US10709770B2 (en) 2013-07-31 2020-07-14 Mead Johnson Nutrition Company Nutritional compositions containing a prebiotic and lactoferrin and uses thereof
US9609888B2 (en) 2013-07-31 2017-04-04 Mead Johnson Nutrition Company Nutritional compositions containing synergistic combination and uses thereof
US10028519B2 (en) * 2014-03-05 2018-07-24 Mead Johnson Nutrition Company Nutritional compositions containing ceramide and uses thereof
US20150305359A1 (en) * 2014-04-24 2015-10-29 Mead Johnson Nutrition Company Nutritional compositions directed to subjects having cow's milk protein allergies
US20160095339A1 (en) * 2014-10-01 2016-04-07 Mead Johnson Nutrition Company Nutritional composition for gastrointestinal environment to provide improved microbiome and metabolic profile
WO2016086157A1 (en) * 2014-11-26 2016-06-02 Abbott Laboratories Infant formula comprising human milk oligosaccharides, polyunsaturated fatty acids, nucleotides, and lutein
US20170006897A1 (en) * 2015-07-10 2017-01-12 Mead Johnson Nutrition Company Nutritional compositions and methods for promoting cognitive development
US10617701B2 (en) 2015-07-10 2020-04-14 Mead Johnson Nutrition Company Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
US10582714B2 (en) * 2015-07-10 2020-03-10 Mead Johnson Nutrition Company Nutritional compositions and methods for promoting cognitive development
US11478011B2 (en) 2015-12-14 2022-10-25 Societe Des Produits Nestle S.A. Nutritional compositions and infant formula for promoting de novo myealination
EP4233904A3 (en) * 2015-12-14 2024-01-10 Société des Produits Nestlé S.A. Compositions and their use
AU2016374163A1 (en) * 2015-12-14 2018-04-26 Nestec S.A. Nutritional compositions and infant formulas to promote myelination in the brain
CN105638906A (zh) * 2016-01-11 2016-06-08 东北农业大学 一种满足婴儿的脂质个性化营养需求的婴儿配方奶粉
ES2947592T3 (es) 2016-04-04 2023-08-11 Nutricia Nv Composición para su uso en la reducción o prevención del retraso global del desarrollo de los niños
WO2018204670A1 (en) * 2017-05-04 2018-11-08 The Board Of Trustees Of The Leland Stanford Junior University Neurodevelopment-promoting food compositions and kits, systems and methods related thereto
JP7150281B2 (ja) * 2017-07-20 2022-10-11 国立研究開発法人理化学研究所 連続的な上皮を含む網膜組織の成熟化方法
EP3691621B1 (en) * 2017-09-14 2024-03-27 Kilman Clarke, Lewis Neupanex ®: neuroprotective, neuroregenerational,&neurogenesis supporting supplement combination
WO2019060661A1 (en) * 2017-09-22 2019-03-28 Iowa State University Research Foundation, Inc. PROBIOTIC COMPOSITIONS FOR THE PRODUCTION OF DOPAMINE
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof
AU2017445026B2 (en) 2017-12-29 2024-09-05 Kraft Foods Group Brands Llc Improved oxidative stability of oil-in-water emulsions using natural stabilizers
IT202100022427A1 (it) * 2021-08-27 2023-02-27 Buona S P A Soc Benefit Composizione per la maturazione del sistema nervoso centrale
CN117045760B (zh) * 2023-07-20 2025-03-28 深圳市金枫生物医药科技有限公司 一种神经修复组合物及其制备方法和应用
WO2025143715A1 (ko) * 2023-12-26 2025-07-03 주식회사 비케이바이오 인지질 혼합물, 중성지질 및 스핀고리피드를 포함하는 인지기능 개선 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143234B2 (en) * 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US20050013884A1 (en) * 2003-07-16 2005-01-20 Rennels M. Scott Compositions and methods for treating heart disease
AU2004283626B2 (en) * 2003-10-24 2010-07-15 N.V. Nutricia Synbiotic composition for infants
CA2583704C (en) * 2004-10-12 2012-12-11 Katrina Fletcher Beta-serum dairy products, neutral lipid-depleted and/or polar lipid-enriched dairy products, and processes for their production
AU2012203650B2 (en) * 2005-05-23 2014-09-18 Massachusetts Institute Of Technology Compositions containing PUFA and methods of use thereof
ATE509624T1 (de) * 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
WO2011121151A1 (es) * 2010-03-31 2011-10-06 Vegenat, S.A. Suplemento alimenticio funcional especialmente destinado para la nutrición, prevención y mejora en casos de alteraciones neurológicas, neurodegenerativas o trastornos cognitivos
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma

Also Published As

Publication number Publication date
CA2912246A1 (en) 2014-07-17
CN104883909A (zh) 2015-09-02
AU2013372898B2 (en) 2016-12-08
HK1214090A1 (zh) 2016-07-22
IN2015DN04207A (es) 2015-10-16
MX2015008585A (es) 2015-09-04
AR094413A1 (es) 2015-07-29
US20140199265A1 (en) 2014-07-17
RU2015120263A (ru) 2017-02-16
PH12015501504A1 (en) 2015-09-28
BR112015016358A2 (pt) 2017-07-11
AU2013372898A1 (en) 2015-05-28
TW201440669A (zh) 2014-11-01
EP2943079A1 (en) 2015-11-18
SG11201503682VA (en) 2015-06-29
WO2014109862A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
PE20151771A1 (es) Composiciones nutricionales que contienen un componente neurologico y los usos del mismo
NI201500140A (es) Compuestos y composiciones terapéuticos
MX373187B (es) Terapia de combinación para tratar cáncer.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
CL2014003130A1 (es) Compuestos derivados de n-piridinil amidas ciclicas,inhibidores de quinasas pim; composicion farmaceutica que los comprende; combinacion farmaceutica; metodo para tratar enfermedades tales como canceres o un trastorno autoinmune.
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CL2017001046A1 (es) Inhibidoes del bromodominio
MX2019014228A (es) Compuestos de biarilo utiles para el tratamiento de enfermedades humanas en oncologia, neurologia e inmunologia.
MX2020001360A (es) Macrociclos de diarilo como moduladores de la proteina quinasa.
MX2017014375A (es) Moduladores del ccr2.
CL2016000408A1 (es) Composiciones farmaceuticas que contienen diastereomeros macrolidos, metodos para su sintesis y usos terapeuticos.
CR20150316A (es) Compuestos y sus métodos de empleo
CL2014001853A1 (es) Compuestos derivados de pirrol sustituido; procedimiento de preparacion; composicion farmaceutica que los contiene; combinacion farmaceutica; uso para tratar enfermedades tales como canceres y enfermedades del sistema inmunitario.
CL2014002265A1 (es) Método, aparato y sistema para diagnóstico y tratamiento de un trastorno del estado del ánimo, el cual permite aplicar estimulación vestibular giratoria, calórica u optocinética a un individuo.
CO7111276A2 (es) Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met
UY36178A (es) Novedosos derivados de ácido heteroaril-butanoico
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
EP2996554C0 (en) SYSTEM FOR DECREASING EVOKED POTENTIAL (DEEP) MAPPING TO IDENTIFY CRITICAL COMPONENTS OF THE ARRHYTHMOGENIC CIRCUIT IN CARDIAC ARRHYTHMIAS
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
MX378108B (es) Anticuerpos anti-met y composiciones.
CO7071139A2 (es) Tratamiento contra el cáncer cerebral
CO7101239A2 (es) Composiciones derivadas de la quitosana

Legal Events

Date Code Title Description
FA Abandonment or withdrawal